SG11201605868XA - Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient - Google Patents
Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredientInfo
- Publication number
- SG11201605868XA SG11201605868XA SG11201605868XA SG11201605868XA SG11201605868XA SG 11201605868X A SG11201605868X A SG 11201605868XA SG 11201605868X A SG11201605868X A SG 11201605868XA SG 11201605868X A SG11201605868X A SG 11201605868XA SG 11201605868X A SG11201605868X A SG 11201605868XA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer treatment
- pharmaceutical
- composition
- active ingredient
- containing same
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 2
- 239000004480 active ingredient Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1361—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from dental pulp or dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014011729 | 2014-01-24 | ||
PCT/JP2015/051887 WO2015111712A1 (ja) | 2014-01-24 | 2015-01-23 | 癌治療用医薬組成物及びその組成物を有効成分とする癌治療用医薬製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201605868XA true SG11201605868XA (en) | 2016-08-30 |
Family
ID=53681509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201605868XA SG11201605868XA (en) | 2014-01-24 | 2015-01-23 | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient |
Country Status (8)
Country | Link |
---|---|
US (1) | US10639355B2 (ja) |
EP (1) | EP3093023B1 (ja) |
JP (2) | JP6166388B2 (ja) |
KR (1) | KR102297734B1 (ja) |
CN (1) | CN106102754B (ja) |
CA (1) | CA2937522C (ja) |
SG (1) | SG11201605868XA (ja) |
WO (1) | WO2015111712A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015111712A1 (ja) * | 2014-01-24 | 2015-07-30 | 株式会社クオリーメン | 癌治療用医薬組成物及びその組成物を有効成分とする癌治療用医薬製剤 |
JP6868565B2 (ja) * | 2015-11-05 | 2021-05-12 | 株式会社Cysay | 不死化幹細胞、及びその作製方法 |
CN106929474B (zh) * | 2017-03-31 | 2021-09-14 | 北京恒峰铭成生物科技有限公司 | 一种m2巨噬细胞诱导剂 |
WO2019126146A1 (en) | 2017-12-19 | 2019-06-27 | Xcell Biosciences, Inc. | Methods of modulating cell phenotype by way of regulating the gaseous environment |
JP6884935B2 (ja) * | 2018-12-20 | 2021-06-09 | 株式会社システムエッヂ | 再生治療用組成物の製造方法 |
CN110951683A (zh) * | 2020-01-06 | 2020-04-03 | 深圳华云生物科技发展有限公司 | 一种牙髓干细胞的制备方法 |
JPWO2022244851A1 (ja) * | 2021-05-19 | 2022-11-24 | ||
WO2023167243A1 (ja) * | 2022-03-01 | 2023-09-07 | 学校法人東京医科大学 | 不死化間葉系幹細胞の上清を含む脱髄疾患治療用医薬組成物、及びその組成物を有効成分とする医薬製剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3897717B2 (ja) * | 2002-04-23 | 2007-03-28 | オリンパス株式会社 | 細胞移植治療材料およびその製造方法 |
KR101685209B1 (ko) * | 2008-07-30 | 2016-12-09 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 유도된 다능성 줄기 세포의 효율적인 확립 방법 |
EP2333047A1 (en) * | 2009-12-09 | 2011-06-15 | Fresenius Medical Care Deutschland GmbH | Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease |
WO2011118795A1 (ja) | 2010-03-26 | 2011-09-29 | 国立大学法人名古屋大学 | 損傷部治療用組成物 |
JP6132459B2 (ja) * | 2011-07-13 | 2017-05-24 | 株式会社 バイオミメティクスシンパシーズ | 間葉系幹細胞の培養上清を含む腸炎の予防・治療剤 |
IN2014DN08862A (ja) * | 2012-03-28 | 2015-05-22 | Quarrymen Corp | |
WO2015111712A1 (ja) * | 2014-01-24 | 2015-07-30 | 株式会社クオリーメン | 癌治療用医薬組成物及びその組成物を有効成分とする癌治療用医薬製剤 |
-
2015
- 2015-01-23 WO PCT/JP2015/051887 patent/WO2015111712A1/ja active Application Filing
- 2015-01-23 SG SG11201605868XA patent/SG11201605868XA/en unknown
- 2015-01-23 CN CN201580005501.1A patent/CN106102754B/zh active Active
- 2015-01-23 JP JP2015559139A patent/JP6166388B2/ja active Active
- 2015-01-23 CA CA2937522A patent/CA2937522C/en active Active
- 2015-01-23 KR KR1020167021909A patent/KR102297734B1/ko active IP Right Grant
- 2015-01-23 US US15/113,646 patent/US10639355B2/en active Active
- 2015-01-23 EP EP15740157.1A patent/EP3093023B1/en active Active
-
2017
- 2017-06-22 JP JP2017121895A patent/JP6351799B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3093023B1 (en) | 2020-11-04 |
CN106102754A (zh) | 2016-11-09 |
EP3093023A1 (en) | 2016-11-16 |
JP6351799B2 (ja) | 2018-07-04 |
CA2937522A1 (en) | 2015-07-30 |
KR20160120726A (ko) | 2016-10-18 |
JP2017160264A (ja) | 2017-09-14 |
EP3093023A4 (en) | 2017-10-11 |
JP6166388B2 (ja) | 2017-07-19 |
KR102297734B1 (ko) | 2021-09-03 |
JPWO2015111712A1 (ja) | 2017-03-23 |
US20170007677A1 (en) | 2017-01-12 |
CN106102754B (zh) | 2020-04-17 |
CA2937522C (en) | 2022-08-23 |
US10639355B2 (en) | 2020-05-05 |
WO2015111712A1 (ja) | 2015-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
EP3263135A4 (en) | Pharmaceutical composition for treating cancer comprising microrna as active ingredient | |
IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
FI3674298T3 (fi) | Substituoituja indatsoleja, menetelmä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia valmisteita sekä niiden käyttö lääkkeiden valmistukseen | |
IL247062A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical preparations containing them | |
EP3111931A4 (en) | Pharmaceutical composition for cancer treatment containing gossypol and phenformin as active ingredients | |
GB201411465D0 (en) | Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer | |
IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
IL253520B (en) | Macrocyclic compounds, their preparation and pharmaceutical preparations containing them | |
SG11201605868XA (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
IL265970B (en) | Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine | |
EP3297640A4 (en) | Pharmaceutical co-crystal composition and use thereof | |
ZA201802033B (en) | Heteroaryl compounds and their use as therapeutic drugs | |
IL250267A0 (en) | History of indolizine, their preparation and pharmaceutical preparations containing them | |
HK1245086A1 (zh) | 處方藥物組成及其製備和使用 | |
EP3328864A4 (en) | COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS | |
HK1245085A1 (zh) | 處方藥物組成及其製備和使用 | |
HK1217303A1 (zh) | 種治療白血病的藥物組合物及其製備方法 | |
IL258977B (en) | Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them | |
SG11201610636VA (en) | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor | |
GB201406172D0 (en) | Therapy and pharmaceutical composition | |
IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
EP3148570A4 (en) | Pharmaceutical composition for preventing or treating skin rash | |
SG11201608845PA (en) | Cosmetic composition containing mentha haplocalyx as active ingredient | |
PL3313370T3 (pl) | Okulistyczna kompozycja farmaceutyczna |